Anti-Influenza A, Nucleocapsid

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

This monoclonal antibody is purified from ascites fluid or culture medium by protein A chromatography or sequential differential precipitations.

This product contains no stabilizing proteins and should be stored at 2-8°C until ready to use.

Ships Overnight on Blue Ice

ELISA Recommended starting range 1:20-1:200
IF Recommended starting range 1:10-1:50

Anti-Influenza A, Nucleoprotein (Clone IA-902) is specific for the Influenza A nucleocapsid.

There are four types of Influenza (flu) viruses: type A, B, C, and D. Influenza A and B viruses are routinely spread in people and other mammals, while also known for seasonal flu epidemics each year. Influenza A is the genus Alphainfluenzavirus of the virus family Orthomyxoviridae. Influenza A is classified into two main protein subtypes, hemagglutinin (HA) and neuraminidase (NA), located on the surface of the virus. Breaking down the proteins further, there are 18 hemagglutinin subtypes and 11 different neuraminidase subtypes¹. Influenza A can be even further classified into specific clades (also known as groups) and sub-clades (also known as sub-groups) based on similarity of their HA/NA gene sequences¹. The Nucleocapsid protein or nucleoprotein (NP) of the influenza virus A negative-strand RNA’s primary function is to encapsulate the virus genome for the purpose of RNA transcription, replication and packaging². Specifically, NP is the most abundant viral protein in infected cells², therefore the NP can be and has been used for anti-influenza drug development³. The NP of influenza A and B viruses share up to 38% of their amino acid sequence, indicating region functionality differences at the amino acid level⁴.

1. Types of Influenza viruses (2019) Center for Disease Control and Prevention.
2. Hu Y, Sneyd H, et al. (2017) Curr Top med Chem. 2017; 17(20): 2271–2285.
3. Portela A, Digard P. (2012) J. Gen Virol. 2002 Apr;83(Pt 4):723-734.
4. Sherry L, Smith M, et al. (2014) Journal of Virology. 2014; 88(21); 12326-12338. DOI https://doi.org/10.1128/JVI.01542-14